NET INCOME ATTRIBUTABLE TO SHAREHOLDERS. Net income attributable to shareholders for the third quarter of fiscal 2012 increased by 52.5% to RMB39.5 million ($6.3 million) from RMB25.9 million in the prior year period, mainly due to the discrete tax benefit of RMB7.8 million ($1.2 million) from the preferential tax treatment for our Beijing subsidiary, and a RMB3.5 million ($0.6 million) exchange rate gain during the quarter. Under the preferential tax treatment, the Beijing subsidiary is qualified for a reduced tax rate of 15% through December 31, 2013, compared to 25% in previous quarters. Net margin for the third quarter of fiscal 2012 rose to 41.6% from 28.6% in the prior year period. Basic and diluted earnings per share for the third quarter of fiscal 2012 were RMB0.54 ($0.09).
LIQUIDITY. As of December 31, 2011, the Company had cash and cash equivalents of RMB716.7 million ($113.9 million) compared to RMB611.4 million as of March 31, 2011. The Company had bank loan borrowings of RMB45.0 million ($7.2 million) as of December 31, 2011.
First Nine Months Fiscal 2012 Financial ResultsFor first nine months of fiscal 2012, total revenues increased 14.6% to RMB280.7 million ($44.6 million) from RMB244.9 million in the prior year period. The increase was largely attributable to the processing fee increase effective from April 2011 and the expansion of the Company's accumulated subscriber base to 225,418 subscribers. During t
|SOURCE China Cord Blood Corporation|
Copyright©2010 PR Newswire.
All rights reserved